Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients.
Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
Department of Haematology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Haematological Malignancy Diagnostic Service, St. James's University Hospital, Leeds, UK.
Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, Leeds, UK.
Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
Molecular and Population Genetics, The Institute of Cancer Research, London, UK.
Department of Haematology, University of Newcastle, Newcastle Upon Tyne, UK.
Division of Molecular Pathology, The Institute of Cancer Research, London, UK. [email protected]
- Published Article
- Publication Date
Nov 01, 2020
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 11/12/2020 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/32157174